Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Urology. 2019 May 25;131:176–183. doi: 10.1016/j.urology.2019.05.012

Figure 1. Frequency of Beneficiaries Treated and Providers Prescribing Abiraterone or Enzalutamide in Medicare Part D.

Figure 1

The bars indicate the frequency of patients prescribed abiraterone (orange) and enzalutamide (blue) each year and the frequency of providers writing prescriptions for the treatments, including those urologists and non-urologists who were moderate-high prescribers.